TICKERNERD
Menu
IRIXIRIXHealthcare · Medical Devices

IRIX Stock Forecast: IRIDEX Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.66
−2.94% on the day

The 1 Wall Street analysts covering IRIDEX Corp. hold a median 12-month price target of $2.75 — +316.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$11.5M
Ticker Nerd rank
80 / 100
Median analyst target
$2.75
Analysts covering
1
Revenue$12.6M−7.4% y/y
Operating income−$1.0M
Net income−$1.3M
Free cash flow$124K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.7%
1M
−25.8%
YTD
−42.1%
1Y
−51.8%
From 52W high
−57.7%
From 52W low
0.0%
$0.66
$1.56
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IRIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores IRIDEX Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
92
Accruals
78
Issuance
76
Value
70
Quality
68
Volatility
66
Growth
61
Momentum
44
Revisions
33

Size (92): Smaller than most of the companies we track.

Revisions (33): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IRIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IRIX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00$2.50$3.00Oct 25Jan 26Apr 26Jul 26IRIXHigh $2.75Median $2.75Low $2.75

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $2.75Median $2.75High $2.75

The green dot is the last close — the median target sits +316.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 May 2024StifelMaintainsHold$2.00
15 May 2024StifelMaintainsHold—
26 Aug 2022StifelDowngradeHold—
12 May 2021Roth CapitalMaintainsBuy—
3 Mar 2021Roth CapitalMaintainsBuy—
13 Jan 2021Roth CapitalMaintainsBuy—
12 May 2020StifelMaintainsBuy—
4 Jan 2019StifelMaintainsBuy—
4 Jan 2019Stifel NicolausMaintainsBuy—
26 Oct 2018StifelInitiatesBuy—
26 Oct 2018Stifel NicolausInitiatesBuy—
21 Dec 2016Roth CapitalInitiatesBuy—
26 Jan 2016Singular ResearchInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IRIX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IRIX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, IRIDEX Corp. returned −51.8% against +17.5% for the S&P 500, dividends included.

IRIX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26IRIXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IRIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

IRIDEX Corp. (IRIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.5×

Cheaper than 86% of US stocks

Price / sales
0.2×

Cheaper than 92% of US stocks

Price / book
3.2×

Cheaper than 31% of US stocks

EV / EBITDA
−6.5×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
−7.4%

Higher than 18% of US stocks

Earnings growth (YoY)
—
Gross margin
34.2%

Higher than 41% of US stocks

Operating margin
−8.2%

Higher than 25% of US stocks

Net margin
−6.9%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−73.1%

Higher than 17% of US stocks

Return on assets
−5.9%

Higher than 31% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

IRIDEX Corp. (IRIX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • IRIDEX Corp. has a market value of $11.5M and an enterprise value of $16.9M.

  • Revenue in the twelve months to 30 June 2026: $51.6M. The latest quarter shrank 7.4% year on year.

  • Net income over the same four quarters: −$3.5M, a −6.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.20.

  • Free cash flow in the twelve months to 30 June 2026: −$2.0M.

  • Shares outstanding: 17.4M.

  • Trailing P/E: −2.5×; forward P/E: 46.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • IRIDEX Corp. employs 93 people — $555K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

IRIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
IRIXIRIDEX Corp.$11.5M
80
SINTSINTX Technologies, Inc.$11.4M
27
ADGMAdagio Medical Holdings, Inc.$11.9M
37
PMIPicard Medical, Inc.$12.5M
25
BMRABiomerica, Inc.$10.3M
17
HSCSHeartSciences, Inc.$13.2M
31
NMTCNeuroOne Medical Technologies Corp.$14.2M
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own IRIDEX Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IRIX news & analysis

IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%

Zacks Investment Research · 25 Aug 2026negative

IRIDEX reported a year-over-year widening loss per share in Q2, with revenues declining due to Middle East disruptions and reduced sell-through in China weighing on retina sales, though the Cyclo G6 product family continued to grow. The company's stock fell 15% following the report.

Why it matters — Investors tracking IRIDEX would care because the quarter shows ongoing headwinds in the retina segment that are offsetting progress in the Cyclo G6 product line.

IRIDEX Corporation (IRIX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 19 Aug 2026neutral

IRIDEX Corporation held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha. The call covered the company's second-quarter financial results and business update for fiscal 2026.

Why it matters — IRIX watchers would care because the earnings call transcript provides direct insight into the company's latest quarterly performance and management commentary.

Iridex Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 18 Aug 2026neutral

Iridex Corporation reported its financial results for the second quarter ended July 4, 2026, in a press release issued on August 18, 2026. The company, which provides laser-based medical systems for glaucoma and retinal disease treatment, disclosed its quarterly performance figures.

Why it matters — IRIX watchers would care because the report provides an update on the company's financial performance for the quarter, a key indicator of its business health.

Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026

GlobeNewsWire · 4 Aug 2026neutral

Iridex Corporation announced it will release its second quarter 2026 financial results and provide a business update after the close of trading on August 18, 2026.

Why it matters — Investors tracking IRIX will learn the company's second-quarter 2026 performance and outlook when the results are published on August 18.

FAQ

Frequently asked questions about IRIX stock

What is the IRIX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering IRIDEX Corp. have a median 12-month price target of $2.75, with estimates ranging from $2.75 to $2.75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IRIX stock a buy right now?

Of the 1 analysts covering IRIDEX Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IRIDEX Corp. 80 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IRIX?

As at 12 Sept 2026, IRIDEX Corp. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

Will IRIX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +316.7% from the last close, and Ticker Nerd's factor model ranks IRIDEX Corp. 80 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IRIX stock forecast for 2030?

No analyst covering IRIDEX Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.75 to $2.75 over the next 12 months.

How has IRIX stock performed over the past year?

IRIDEX Corp. returned -51.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IRIDEX Corp. do?

Iridex Corp. is an ophthalmic medical technology company that develops, manufactures, and markets laser-based medical systems, delivery devices, and consumable instrumentation for eye care professionals.

What is the latest news on IRIX?

The most recent item we track (Zacks Investment Research, 25 Aug 2026): "IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%". IRIDEX reported a year-over-year widening loss per share in Q2, with revenues declining due to Middle East disruptions and reduced sell-through in China weighing on retina sales, though the Cyclo G6 product family continued to grow. The company's stock fell 15% following the report.

Company

About IRIDEX Corp.

Iridex Corp. is an ophthalmic medical technology company that develops, manufactures, and markets laser-based medical systems, delivery devices, and consumable instrumentation for eye care professionals. The company’s products are used in the treatment of glaucoma, retinal disorders, diabetic eye disease, and other sight-threatening conditions, supporting both office-based procedures and surgical settings. Iridex’s portfolio includes laser consoles, delivery platforms, and single-use probes designed to work with its proprietary MicroPulse technology and other treatment systems. The company serves ophthalmologists, hospitals, surgical centers, research institutions, veterinary practices, and clinics through direct sales in the United States and distributor networks internationally. Headquartered in Mountain View, California, and founded in 1989, Iridex plays a specialized role in the medical device market by providing tools focused on precision ophthalmic therapy and recurring consumable use.

CEO Mr. Patrick Mercer · 93 employees · United States · https://www.iridex.com